Terms: = Pancreatic cancer AND ERG, P11308, 2078
58 results:
1. PTEN, erg, SPINK1, and TFF3 Status and Relationship in a Prostate cancer Cohort from Jordanian Arab Population.
Al Bashir S; Alorjani MS; Kheirallah K; Al Hamad M; Haddad HK; Al-Dwairy A; Bani-Fawwaz BA; Aldaoud N; Halalsheh O; Amawi S; Matalka II
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256434
[No Abstract] [Full Text] [Related]
2. The Usefulness of Elastin Staining to Detect Vascular Invasion in cancer.
Gonzalez J; Bahmad HF; Ocejo S; Abreu A; Popp M; Gogola S; Fernandez V; Recine M; Poppiti R
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894944
[TBL] [Abstract] [Full Text] [Related]
3. Associations between Etiologic or Prognostic Tumor Tissue Markers and Neighborhood Contextual Factors in Male Health Professionals Diagnosed with Prostate cancer.
Iyer HS; Kensler KH; Vaselkiv JB; Stopsack KH; Roscoe C; Bandera EV; Qin B; Jang TL; Lotan TL; James P; Hart JE; Mucci LA; Laden F; Rebbeck TR
Cancer Epidemiol Biomarkers Prev; 2023 Aug; 32(8):1120-1123. PubMed ID: 37249585
[TBL] [Abstract] [Full Text] [Related]
4. Reappraisal of Malignant Risk Assessment for Small (≤20 mm) Non-functioning pancreatic Neuroendocrine Tumors.
Nanno Y; Toyama H; Matsumoto I; Uemura J; Asari S; Goto T; Lee D; Murakami T; Komatsu S; Yanagimoto H; Kido M; Ajiki T; Okano K; Takeyama Y; Fukumoto T
Ann Surg Oncol; 2023 Jun; 30(6):3493-3500. PubMed ID: 36795254
[TBL] [Abstract] [Full Text] [Related]
5. Determination of erg(+), EZH2, NKX3.1, and SPINK-1 subtypes to evaluate their association with clonal origin and disease progression in multifocal prostate cancer.
Segura-Moreno YY; Sanabria-Salas MC; Mesa-López De Mesa JA; Varela-Ramirez R; Acosta-Vega NL; Serrano ML
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1728. PubMed ID: 36199157
[TBL] [Abstract] [Full Text] [Related]
6. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
[TBL] [Abstract] [Full Text] [Related]
7. Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.
Fontugne J; Cai PY; Alnajar H; Bhinder B; Park K; Ye H; Beg S; Sailer V; Siddiqui J; Blattner-Johnson M; Croyle JA; Noorzad Z; Calagua C; MacDonald TY; Axcrona U; Bogaard M; Axcrona K; Scherr DS; Sanda MG; Johannessen B; Chinnaiyan AM; Elemento O; Skotheim RI; Rubin MA; Barbieri CE; Mosquera JM
JCI Insight; 2022 Feb; 7(4):. PubMed ID: 35050902
[TBL] [Abstract] [Full Text] [Related]
8. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
[TBL] [Abstract] [Full Text] [Related]
9. Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.
Abdelsalam RA; Khalifeh I; Box A; Kalantarian M; Ghosh S; Abou-Ouf H; Lotfi T; Shahait M; Palanisamy N; Bismar TA
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1701-1709. PubMed ID: 32350606
[TBL] [Abstract] [Full Text] [Related]
10. Clonal evaluation of prostate cancer molecular heterogeneity in biopsy samples by dual immunohistochemistry and dual RNA in situ hybridization.
Dedigama-Arachchige P; Carskadon S; Li J; Loveless I; Alhamar M; Peabody JO; Stricker H; Chitale DA; Rogers CG; Menon M; Gupta NS; Bismar TA; Williamson SR; Palanisamy N
Mod Pathol; 2020 Sep; 33(9):1791-1801. PubMed ID: 32238875
[TBL] [Abstract] [Full Text] [Related]
11. Characterization of Inhibitory Effectiveness in Hyperpolarization-Activated Cation Currents by a Group of
Kuo PC; Liu YC; Lo YC; Wu SN
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32070065
[TBL] [Abstract] [Full Text] [Related]
12. Adult pancreatic cavernous hemangioma: case presentation of a benign tumor with a complex composition.
Lianyuan T; Yafeng W; Haibo Y; Yadong D; Jiahao M; Yuanxiang L; Deyu L
BMC Gastroenterol; 2019 Nov; 19(1):197. PubMed ID: 31771513
[TBL] [Abstract] [Full Text] [Related]
13. Prostate cancer Risk Stratification in Men With a Clinical Suspicion of Prostate cancer Using a Unique Biparametric MRI and Expression of 11 Genes in Apparently Benign Tissue: Evaluation Using Machine-Learning Techniques.
Montoya Perez I; Jambor I; Pahikkala T; Airola A; Merisaari H; Saunavaara J; Alinezhad S; Väänänen RM; Tallgrén T; Verho J; Kiviniemi A; Ettala O; Knaapila J; Syvänen KT; Kallajoki M; Vainio P; Aronen HJ; Pettersson K; Boström PJ; Taimen P
J Magn Reson Imaging; 2020 May; 51(5):1540-1553. PubMed ID: 31588660
[TBL] [Abstract] [Full Text] [Related]
14. Clonal evaluation of early onset prostate cancer by expression profiling of erg, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.
Lu Z; Williamson SR; Carskadon S; Arachchige PD; Dhamdhere G; Schultz DS; Stricker H; Peabody JO; Jeong W; Chitale DA; Bismar TA; Rogers CG; Menon M; Gupta NS; Palanisamy N
Prostate; 2020 Jan; 80(1):38-50. PubMed ID: 31584209
[TBL] [Abstract] [Full Text] [Related]
15. Normal T
Tirkes T; Mitchell JR; Li L; Zhao X; Lin C
Abdom Radiol (NY); 2019 Sep; 44(9):3133-3138. PubMed ID: 31139885
[TBL] [Abstract] [Full Text] [Related]
16. Clinical significance and EZH2, erg and SPINK1 protein expression in pure and mixed ductal adenocarcinoma of the prostate.
Patil PA; McKenney JK; Reynolds JP; Przybycin CG; Magi-Galluzzi C
Histol Histopathol; 2019 Apr; 34(4):381-390. PubMed ID: 30246858
[TBL] [Abstract] [Full Text] [Related]
17. Comparison of erg and SPINK1 expression among incidental and metastatic prostate cancer in Japanese men.
Koide H; Kimura T; Inaba H; Sato S; Iwatani K; Yorozu T; Furusato B; Kamata Y; Miki J; Kiyota H; Takahashi H; Egawa S
Prostate; 2019 Jan; 79(1):3-8. PubMed ID: 30051483
[TBL] [Abstract] [Full Text] [Related]
18. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic pancreatic cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stainthorpe A; Greenhalgh J; Bagust A; Richardson M; Boland A; Beale S; Duarte R; Kotas E; Banks L; Palmer D
Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
[TBL] [Abstract] [Full Text] [Related]
19. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating pancreatic cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Abdulla A; Bagust A; Beale S; Richardson M; Stainthorpe A; Boland A; Kotas E; McEntee J; Palmer D
Pharmacoeconomics; 2018 Mar; 36(3):289-299. PubMed ID: 29178025
[TBL] [Abstract] [Full Text] [Related]
20. Molecular alterations in prostate cancer and association with MRI features.
Lee D; Fontugne J; Gumpeni N; Park K; MacDonald TY; Robinson BD; Sboner A; Rubin MA; Mosquera JM; Barbieri CE
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):430-435. PubMed ID: 28762374
[TBL] [Abstract] [Full Text] [Related]
[Next]
